Showing results (221-230 of 537) with videos related to
Sort By:
Pageof 54
American Journal of Therapeutics|March 7, 2019
Therapeutic Advances in the Management of Cardiogenic ShockOvidiu Chioncel, Sean P Collins, Andrew P Ambrosy, et al.Frontiers in Oncology|October 4, 2021
Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet TherapyAbigail Pepin, Sarthak Shah, Monica Pernia, et al.European Journal of Heart Failure|October 9, 2009
Adjusting for clinical covariates improves the ability of B-type natriuretic peptide to distinguish cardiac from non-cardiac dyspnoea: a sub-study of HEARD-ITR Kevin Rogers, Josef Stehlik, Gregory J Stoddard, et al.Heart Failure Reviews|April 4, 2018
Expanded algorithm for managing patients with acute decompensated heart failureJoyce N Njoroge, Baljash Cheema, Andrew P Ambrosy, et al.Clinical and Experimental Emergency Medicine|July 13, 2019
Potential impact of cardiology phone-consultation for patients risk-stratified by the HEART pathwayKen Monahan, Margaret Pan, Chinonso Opara, et al.Acta Oncologica (Stockholm, Sweden)|May 15, 2015
Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancerThomas P Kole, Michael Tong, Binbin Wu, et al.Cureus|April 12, 2021
Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate CancerAbigail Pepin, Monica Pernia, Malika T Danner, et al.Journal of the American College of Emergency Physicians Open|March 1, 2021
Understanding timely STEMI treatment performance: A 3-year retrospective cohort study using diagnosis-to-balloon-time and care subintervalsMaame Yaa A B Yiadom, Olayemi O Olubowale, Cathy A Jenkins, et al.Radiation Oncology (London, England)|August 14, 2013
Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancerSumit Sood, Andrew W Ju, Honkung Wang, et al.Scientific Reports|July 7, 2019
MicroRNA-214 targets PTK6 to inhibit tumorigenic potential and increase drug sensitivity of prostate cancer cellsPatrice Cagle, Suryakant Niture, Anvesha Srivastava, et al.Pageof 54